KR20240140102A - 알도스테론 신타아제의 주기적 억제에 의해 고혈압을 치료하는 방법 - Google Patents

알도스테론 신타아제의 주기적 억제에 의해 고혈압을 치료하는 방법 Download PDF

Info

Publication number
KR20240140102A
KR20240140102A KR1020247027543A KR20247027543A KR20240140102A KR 20240140102 A KR20240140102 A KR 20240140102A KR 1020247027543 A KR1020247027543 A KR 1020247027543A KR 20247027543 A KR20247027543 A KR 20247027543A KR 20240140102 A KR20240140102 A KR 20240140102A
Authority
KR
South Korea
Prior art keywords
subject
cyp
beta
hydroxylase inhibitor
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027543A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 로드먼
브라이언 테일러 슬링스비
존 콩글턴
히데토시 시미즈
요시야스 오타
마도리 오리하시
Original Assignee
미네랄리스 테라퓨틱스, 아이엔씨.
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미네랄리스 테라퓨틱스, 아이엔씨., 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미네랄리스 테라퓨틱스, 아이엔씨.
Publication of KR20240140102A publication Critical patent/KR20240140102A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247027543A 2022-01-19 2023-01-19 알도스테론 신타아제의 주기적 억제에 의해 고혈압을 치료하는 방법 Pending KR20240140102A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263300967P 2022-01-19 2022-01-19
US63/300,967 2022-01-19
US202263400301P 2022-08-23 2022-08-23
US63/400,301 2022-08-23
PCT/IB2023/050444 WO2023139506A1 (en) 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase

Publications (1)

Publication Number Publication Date
KR20240140102A true KR20240140102A (ko) 2024-09-24

Family

ID=87347916

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027543A Pending KR20240140102A (ko) 2022-01-19 2023-01-19 알도스테론 신타아제의 주기적 억제에 의해 고혈압을 치료하는 방법

Country Status (7)

Country Link
US (1) US20250099475A1 (https=)
EP (1) EP4466021A4 (https=)
JP (1) JP2025503015A (https=)
KR (1) KR20240140102A (https=)
CA (1) CA3240577A1 (https=)
TW (1) TW202339758A (https=)
WO (1) WO2023139506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025527706A (ja) * 2022-08-23 2025-08-22 ミネラリス・セラピューティクス・インコーポレイテッド 肥満対象における高血圧を治療する方法
CA3265668A1 (en) * 2022-08-23 2024-02-29 Mineralys Therapeutics, Inc. METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886117C (en) * 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
JP2023546970A (ja) * 2020-10-26 2023-11-08 ミネラリス・セラピューティクス・インコーポレイテッド 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Also Published As

Publication number Publication date
CA3240577A1 (en) 2023-07-27
EP4466021A4 (en) 2026-01-14
US20250099475A1 (en) 2025-03-27
WO2023139506A1 (en) 2023-07-27
JP2025503015A (ja) 2025-01-30
EP4466021A1 (en) 2024-11-27
TW202339758A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
Calhoun et al. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension
EP3607942B1 (en) Medicament and method of diagnosis
US9387249B2 (en) Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
KR20240140102A (ko) 알도스테론 신타아제의 주기적 억제에 의해 고혈압을 치료하는 방법
Mulatero et al. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone‐to‐renin ratio, an indicator of sodium retention, in healthy volunteers
Ubaid‐Girioli et al. Aldosterone escape with diuretic or angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension
EP3352734B1 (en) Treatment of alopecia areata
CN110785168A (zh) 用于预防或治疗猫的全身性疾病的血管收缩素ii受体拮抗剂
JP6934859B2 (ja) 腎疾患の治療のための医薬
US20260053811A1 (en) Methods of treating hypertension in obese subjects
US20260053812A1 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
TW202519234A (zh) 以洛倫德羅斯塔(lorundrostat)及二或多種降血壓藥物之組合治療高血壓之方法
GB2503396A (en) Treatment of subclinical Cushing's syndrome and/or incidentaloma
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
HK1257770B (en) Treatment of alopecia areata

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)